WO2006124884A3 - Dosing regimen - Google Patents

Dosing regimen Download PDF

Info

Publication number
WO2006124884A3
WO2006124884A3 PCT/US2006/018897 US2006018897W WO2006124884A3 WO 2006124884 A3 WO2006124884 A3 WO 2006124884A3 US 2006018897 W US2006018897 W US 2006018897W WO 2006124884 A3 WO2006124884 A3 WO 2006124884A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosing regimen
tert
drug
dephenyl
debenzoyl
Prior art date
Application number
PCT/US2006/018897
Other languages
French (fr)
Other versions
WO2006124884A2 (en
Inventor
Maurizio Voi
Original Assignee
Bristol Myers Squibb Co
Maurizio Voi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Maurizio Voi filed Critical Bristol Myers Squibb Co
Publication of WO2006124884A2 publication Critical patent/WO2006124884A2/en
Publication of WO2006124884A3 publication Critical patent/WO2006124884A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

This invention relates to a twice weekly administration of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel that has been found to reduce the neurotoxicity of the drug and allow for better patient compliance in the use of this oral cancer drug.
PCT/US2006/018897 2005-05-13 2006-05-12 Dosing regimen WO2006124884A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68069805P 2005-05-13 2005-05-13
US60/680,698 2005-05-13

Publications (2)

Publication Number Publication Date
WO2006124884A2 WO2006124884A2 (en) 2006-11-23
WO2006124884A3 true WO2006124884A3 (en) 2007-04-19

Family

ID=37432028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018897 WO2006124884A2 (en) 2005-05-13 2006-05-12 Dosing regimen

Country Status (2)

Country Link
TW (1) TW200722080A (en)
WO (1) WO2006124884A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476242B1 (en) * 1997-12-31 2002-11-05 Bristol-Myers Squibb Company 2-aroyl-4-acyl paclitaxel (Taxol) analogs
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476242B1 (en) * 1997-12-31 2002-11-05 Bristol-Myers Squibb Company 2-aroyl-4-acyl paclitaxel (Taxol) analogs
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLUMMER R. ET AL.: "Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies", CLIN. CANCER RES., vol. 8, no. 9, 2002, pages 2788 - 2797, XP003010610 *

Also Published As

Publication number Publication date
TW200722080A (en) 2007-06-16
WO2006124884A2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
TWI315203B (en) Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments
IL236426B (en) Use of a compound in combination with bortezomib in the preparation of a medicament for treating a neoplastic disease and pharmaceutical composition comprising a compound and bortezomib
IL171683A (en) Immunosuppressant compounds, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
EP1635762A4 (en) Low dose pharmaceutical powders for inhalation
TWI367096B (en) Vitamin-receptor binding drug delivery conjugates and pharmaceutical compositions
IL166286A0 (en) Multicomponent pharmaceutical dosage form
UA105210C2 (en) Anti-cancer vaccine and use thereof
EP1919288A4 (en) Medicaments containing famotidine and ibuprofen and administration of same
IL178822A (en) 4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders
HUP0401174A3 (en) Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
EP1594477A4 (en) Active drug delivery in the gastrointestinal tract
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
EP1651195A4 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
GB0313604D0 (en) Delivery device for powdered medicament
HK1076387A1 (en) Use in the preparation of a combination medicament for the treatment or prevention of an immunoinflammatory disorder
IL193094A (en) Use of aplidine and another drug in the manufacture of a medicament for the treatment of cancer wherein the combination of both drugs provides a synergistic effect
IL183929A0 (en) Use of inerferon - ?? in the preparation of a medicament
EP1745793A4 (en) Adsorbent for oral administration, therapeutic or preventive agent for kidney disease, and therapeutic or preventive agent for liver disease
EP1658105A4 (en) Pharmaceutical metered dose inhaler and methods relating thereto
IL173847A0 (en) Pharmaceutical composition in a form of anhydrous self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2008003050A3 (en) Gallium nitrate formulations
IL172704A (en) Pharmaceutical composition comprising a salinosporamide compound and use thereof in the manufacture of a medicament for treating cancer
HK1100352A1 (en) Solid medicament of oral administration and preparation thereof
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
ZA200701578B (en) Combination anticancer therapy and pharmaceutical compositions therefore

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06752552

Country of ref document: EP

Kind code of ref document: A2